Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting.
Erreni M, D'Autilia F, Avigni R, Bolli E, Arnouk SM, Movahedi K, Debie P, Anselmo A, Parente R, Vincke C, van Leeuwen FWB, Allavena P, Garlanda C, Mantovani A, Doni A, Hernot S, Van Ginderachter JA. Erreni M, et al. Among authors: bolli e. Theranostics. 2023 Jan 1;13(1):355-373. doi: 10.7150/thno.77560. eCollection 2023. Theranostics. 2023. PMID: 36593955 Free PMC article.
Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages.
De Vlaeminck Y, Lecocq Q, Giron P, Heirman C, Geeraerts X, Bolli E, Movahedi K, Massa S, Schoonooghe S, Thielemans K, Goyvaerts C, Van Ginderachter JA, Breckpot K. De Vlaeminck Y, et al. Among authors: bolli e. J Control Release. 2019 Apr 10;299:107-120. doi: 10.1016/j.jconrel.2019.02.023. Epub 2019 Feb 21. J Control Release. 2019. PMID: 30797866
Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies.
Bolli E, Scherger M, Arnouk SM, Pombo Antunes AR, Straßburger D, Urschbach M, Stickdorn J, De Vlaminck K, Movahedi K, Räder HJ, Hernot S, Besenius P, Van Ginderachter JA, Nuhn L. Bolli E, et al. Adv Sci (Weinh). 2021 Mar 8;8(10):2004574. doi: 10.1002/advs.202004574. eCollection 2021 May. Adv Sci (Weinh). 2021. PMID: 34026453 Free PMC article.
Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophages.
Bonelli S, Geeraerts X, Bolli E, Keirsse J, Kiss M, Pombo Antunes AR, Van Damme H, De Vlaminck K, Movahedi K, Laoui D, Raes G, Van Ginderachter JA. Bonelli S, et al. Among authors: bolli e. FEBS J. 2018 Feb;285(4):777-787. doi: 10.1111/febs.14202. Epub 2017 Sep 6. FEBS J. 2018. PMID: 28834216 Free article. Review.
Stromal-targeting radioimmunotherapy mitigates the progression of therapy-resistant tumors.
Bolli E, D'Huyvetter M, Murgaski A, Berus D, Stangé G, Clappaert EJ, Arnouk S, Pombo Antunes AR, Krasniqi A, Lahoutte T, Gonçalves A, Vuylsteke M, Raes G, Devoogdt N, Movahedi K, Van Ginderachter JA. Bolli E, et al. J Control Release. 2019 Nov 28;314:1-11. doi: 10.1016/j.jconrel.2019.10.024. Epub 2019 Oct 15. J Control Release. 2019. PMID: 31626860
Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development.
De Vlaeminck Y, Bonelli S, Awad RM, Dewilde M, Rizzolio S, Lecocq Q, Bolli E, Santos AR, Laoui D, Schoonooghe S, Tamagnone L, Goyvaerts C, Mazzone M, Breckpot K, Van Ginderachter JA. De Vlaeminck Y, et al. Among authors: bolli e. Cancers (Basel). 2020 Nov 30;12(12):3582. doi: 10.3390/cancers12123582. Cancers (Basel). 2020. PMID: 33266104 Free PMC article.
65 results